Sharechat Logo

AFT - Retirement of Anita Baldauf

Monday 1st July 2024

Text too small?

AFT Pharmaceuticals (NZX.AFT, ASX.AFP) independent director Anita Baldauf has announced her intention not to seek re-election and to retire as a director of the company at the upcoming shareholders meeting on Friday 2nd August 2024.

Chair David Flacks said: “On behalf of the Board, I would like to sincerely thank Anita for her valuable contribution and service during her four-year tenure. Her industry knowledge and international finance and marketing experience has been of great assistance to AFT particularly in its continued growth internationally.”

The Board will now commence a recruitment process for a replacement director, and further details will be announced in due course.

 

Released for and on behalf of AFT Pharmaceuticals limited by Malcolm Tubby, Chief Financial Officer.

 

 

For more information:

Investors Media

Dr Hartley Atkinson Richard Inder

Managing Director The Project

AFT Pharmaceuticals Tel: +64 21 645 643

Tel: +64 9488 0232

 

About AFT Pharmaceuticals (ASX:AFP, NZX: AFT )

www.aftpharm.com

AFT Pharmaceuticals are a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over the counter, prescription, and hospital. AFT Pharmaceutical's product portfolio comprises both proprietary and in-licensed products, and includes patented, branded, and generic drugs.

Retirement of Anita Baldauf


  General Finance Advertising    

Comments from our readers

No comments yet

Add your comment:
Your name:
Your email:
Not displayed to the public
Comment:
Comments to Sharechat go through an approval process. Comments which are defamatory, abusive or in some way deemed inappropriate will not be approved. It is allowable to use some form of non-de-plume for your name, however we recommend real email addresses are used. Comments from free email addresses such as Gmail, Yahoo, Hotmail, etc may not be approved.

Related News:

December 27th Morning Report
FBU - Fletcher Building Announces Director Appointment
December 23rd Morning Report
MWE - Suspension of Trading and Delisting
EBOS welcomes finalisation of First PWA
CVT - AMENDED: Bank covenant waiver and trading update
Gentrack Annual Report 2024
December 20th Morning Report
Rua Bioscience announces launch of new products in the UK
TEM - Appointment to the Board of Directors